Aligos Therapeutics Inc (ALGS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 2,186 | 3,945 | 15,529 | 13,907 | 4,359 |
| Gross Profit | 2,186 | 3,945 | 15,529 | 13,907 | 4,359 |
| Operating Expenses | 90,171 | 93,099 | 103,656 | 111,487 | 132,680 |
| Operating Income | -87,985 | -89,154 | -88,127 | -97,580 | -128,321 |
| Other Income | 64,106 | -41,726 | 1,243 | 1,640 | 132 |
| Pre-tax Income | -23,879 | -130,880 | -86,884 | -95,940 | -128,189 |
| Income Tax | 314 | 331 | 795 | 106 | 143 |
| Net Income Continuous | -24,193 | -131,211 | -87,679 | -96,046 | -128,332 |
| Net Income | $-24,193 | $-131,211 | $-87,679 | $-96,046 | $-128,332 |
| EPS Basic Total Ops | -2.45 | -20.94 | -34.20 | -56.25 | -80.50 |
| EPS Basic Continuous Ops | -2.45 | -20.94 | -34.21 | -56.24 | -80.50 |
| EPS Diluted Total Ops | -2.45 | -20.94 | -34.20 | -56.25 | -80.50 |
| EPS Diluted Continuous Ops | -2.45 | -20.94 | -34.21 | -56.24 | -80.50 |
| EPS Diluted Before Non-Recurring Items | -2.45 | -13.58 | -34.00 | -56.25 | -80.50 |
| EBITDA(a) | $-89,243 | $-89,910 | $-85,482 | $-94,064 | $-124,457 |